Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer

• Published in: Zhongguo Zhong xi yi jie he za zhi Vol. 32; no. 6; p. 817
• Main Authors: Qi, Cong, Zhang, Qin-Hua, Li, Jiu-Xian
• Format: Journal Article
• Language: Chinese
• Published: China 01.06.2012
• Subjects: Animals; Apoptosis; bcl-2-Associated X Protein - metabolism; Cell Line, Tumor; Cisplatin - administration & dosage; Cisplatin - pharmacology; Cisplatin - therapeutic use; Drug Resistance, Neoplasm - drug effects; Drug Therapy, Combination; Drugs, Chinese Herbal - administration & dosage; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Platinum - pharmacology; Proto-Oncogene Proteins c-bcl-2 - metabolism
• ISSN: 1003-5370

To observe the effects of Zengmian Yiliu Recipe (ZYR) combined cisplatin on the growth of subcutaneous tumor in nude mice with platinum-resistant ovarian cancer, and to explore its possible mechanisms. The model of ovarian cancer subcutaneous tumor was established in nude mice using platinum-resistant ovarian cancer line COC1/DDP. The mice were randomly divided into six groups, i. e., the high Chinese materia medica (CMM) group, the medium CMM group, the low CMM group, the cisplatin group (DDP), the combined treatment group (with DDP combined CMM), and the control group (with normal saline). The medication lasted for 3 successive weeks. The tumor weight and the tumor inhibition rate were calculated. The expressions of Bcl-associated x protein (Bax) and B-cell lymphoma/leukemia-2 (Bcl-2) were detected using quantitative RT-PCR and immunohistochemical assay. The ultra-structure of tumor cells was observed by electron microscopy. The tumor inhibition rate was the highest in the combined treatment group, being (5